Krishna Vaddi
CEO at Prelude Therapeutics Incorporated
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Prelude Therapeutics Incorporated, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Prelude Therapeutics Incorporated June 9, 202699.8%
-
Prelude Therapeutics Incorporated June 16, 202396.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +675,000 | $0.69 | $465,750 |
| Mar 21, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +15,000 | $0.73 | $10,950 |
| Mar 20, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +5,416 | $0.73 | $3,954 |
| Mar 17, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +9,106 | $0.75 | $6,830 |
| Mar 14, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +29,999 | $0.75 | $22,499 |
| Mar 13, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +50,000 | $0.72 | $36,000 |
| Mar 12, 2025 | Prelude Therapeutics Incorporated | Open-market purchase | +47,500 | $0.71 | $33,725 |
| Dec 31, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +5,000 | $1.21 | $6,050 |
| Dec 30, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +10,000 | $1.20 | $12,000 |
| Dec 19, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +6,888 | $0.89 | $6,130 |
| Dec 18, 2024 | Prelude Therapeutics Incorporated | Open-market purchase | +100,000 | $0.93 | $93,000 |
| May 25, 2023 | Prelude Therapeutics Incorporated | Open-market purchase | +900 | $5.31 | $4,779 |
| May 24, 2023 | Prelude Therapeutics Incorporated | Open-market purchase | +1,000 | $5.01 | $5,010 |
| May 23, 2023 | Prelude Therapeutics Incorporated | Open-market purchase | +11,856 | $5.63 | $66,749 |
Questions about Krishna Vaddi
What boards is Krishna Vaddi on?
Krishna Vaddi sits on the board of Prelude Therapeutics Incorporated.
What company is Krishna Vaddi the CEO of?
Krishna Vaddi is CEO of Prelude Therapeutics Incorporated.
How long has Krishna Vaddi served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.